Aclaris Therapeutics, Inc. (0H8T.L) LSE

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Neal S. Walker	Co-Founder, Chief Executive Officer & Chairman	965,550	1970
Jesse W. Hall	Chief Medical Officer	371,166	1974
Roland Kolbeck	Chief Scientific Officer	492,432	1964
Hugh Davis	President, Chief Operating Officer & Director	555,541	1960
James Loerop	Chief Business Officer	590,160	1965
Kevin Balthaser	Chief Financial Officer	631,710	1987
Matthew Rothman	General Counsel & Corporate Secretary	0	N/A
Jon Jacobsen	Senior Vice President of Chemistry	0	N/A
Nina Samra	Senior Vice President of Clinical Operations	0	N/A
Steve Tucker	Executive Vice President of Project Leadership	0	N/A
William C. Roberts	Senior Vice President of Corporate Communications & Investor Relations	0	1969

Name

Title

Pay

Year Born

Neal S. Walker

Co-Founder, Chief Executive Officer & Chairman

965,550

1970

Jesse W. Hall

Chief Medical Officer

371,166

1974

Roland Kolbeck

Chief Scientific Officer

492,432

1964

Hugh Davis

President, Chief Operating Officer & Director

555,541

1960

James Loerop

Chief Business Officer

590,160

1965

Kevin Balthaser

Chief Financial Officer

631,710

1987

Matthew Rothman

General Counsel & Corporate Secretary

N/A

Jon Jacobsen

Senior Vice President of Chemistry

N/A

Nina Samra

Senior Vice President of Clinical Operations

N/A

Steve Tucker

Executive Vice President of Project Leadership

N/A

William C. Roberts

Senior Vice President of Corporate Communications & Investor Relations

1969

Description

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in the United States, dedicated to discovering and advancing novel therapeutic agents for immune-inflammatory diseases. The company operates through two distinct divisions: Therapeutics and Contract Research. The Therapeutics segment focuses on identifying and developing cutting-edge treatments to address significant unmet medical needs within the realm of immunological and inflammatory conditions. Complementing this, the Contract Research segment offers specialized laboratory services. Aclaris boasts a robust development pipeline, featuring several key drug candidates. These include Zunsemetinib, an MK2 inhibitor, currently being developed to treat moderate to severe rheumatoid and psoriatic arthritis, as well as hidradenitis suppurativa. Another significant asset is ATI-1777, a soft JAK 1/3 inhibitor, targeting moderate to severe atopic dermatitis. Furthermore, the company is progressing with ATI-2138, an ITK/TXK/JAK3 inhibitor for T cell-mediated autoimmune diseases; a Gut-Biased Program aimed at inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, intended for pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics maintains its principal office in Wayne, Pennsylvania.